Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Breast Cancer Research

Fig. 5

From: Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Fig. 5

Serum thymidine kinase 1 (TK1) activity and tumor Ki-67 by time point for individual cases discordant in the direction of changes between TK1 and Ki-67 levels. a and b Line graphs for TK1 activity and Ki-67 levels, respectively, for the three cases discordant when comparing data between cycle 1, day 15 (C1D15), and cycle 1, day 1 (C1D1), time points. c and d Line graphs for TK1 activity and Ki-67 levels, respectively, for the three cases discordant upon comparing data between C1D15 and surgery time points

Back to article page